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Synthetic peptides mimicking a conformational B-cell epitope (M2) of the measles virus fusion protein (MVF) were used for
the immunization of BALB/c mice and the anti-peptide and anti-virus antibody titers induced were compared. Of the panel of
tested peptides, a chimeric peptide consisting of two copies of a T-helper epitope (residues 288–302 of MVF) and one copy
of the mimotope M2 (TTM2) and a multiple antigen peptide with eight copies of M2 (MAP-M2) induced the highest titers of
anti-M2 and anti-MV antibodies. Furthermore, peptides TTM2 and MAP-M2 induced antibodies with highest affinity for the
mimotope and highest avidity for measles virus. Immunization with the MAP-M2 construct induced high titers of high-affinity
anti-M2 antibody despite the absence of a T-helper epitope, and lymphocyte proliferation data suggest that the addition of
M2 to the MAP resulted in the generation of a structure capable of stimulating T-cell help. Sera with anti-M2 reactivity were
pooled according to affinity values for binding to M2, and high- and low-affinity pools were tested for their ability to prevent
MV-induced encephalitis in a mouse model. The high-affinity serum pool conferred protection in 100% of mice, whereas the
lower affinity pool conferred protection to only 50% of animals. These results indicate the potential of mimotopes for use as
synthetic peptide immunogens and highlight the importance of designing vaccines to induce antibodies of high affinity.
© 2000 Academic Press
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The successful identification of T- and B-cell epitopes
from viral proteins has contributed to the concept of the
synthesis of chimeric peptide immunogens composed of
different combinations of both types of epitopes to in-
duce T-helper cell responses and antibody production.
Recent experiments have shown that the amino acid
composition, the number and the orientation of the
epitopes, as well as the use of an adjuvant and the route
of vaccine delivery may influence the level and affinity of
the antibodies elicited (Partidos et al., 1992a, b; Obeid et
l., 1996). This suggests that different ways of antigen
rocessing and presentation may result in the produc-
ion of immunochemically distinct antibodies, and the
ppropriate selection of epitopes to stimulate antibody
nd T-cell responses is fundamental to the design of
ffective peptide vaccines. The inclusion of promiscuous
-cell epitopes in such a vaccine will ensure the stimu-
ation of responses in individuals of different MHC hap-
otypes (Lairmore et al., 1995). A number of such promis-
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98uous T-cell epitopes have been identified; these include
hose from tetanus toxoid (residues 830–843 and 947–
67) (Ho et al., 1990) and the measles virus F protein
residues 288–302) (Partidos and Steward, 1990). Immu-
ization with chimeric peptides made up of the latter
eptide coupled to a linear B-cell epitope (residues 404
o 414 of measles virus fusion (MVF) protein) (peptides
B and TTB) have been shown to induce anti-peptide-
nd anti-virus-specific antibodies. Additionally, the TTB
eptide induced protective immune responses against in
ivo challenge with MV and canine distemper virus
Obeid et al., 1995).
It is very likely that a significant proportion of antibody
esponses to viral proteins and glycoproteins are di-
ected toward conformational rather than linear B-cell
pitopes and combinatorial peptide libraries have been
sed to generate peptide mimics (mimotopes) of these
pitopes, several of which have been identified and char-
cterized. These include those mimicking two different
pitopes from the human hepatitis B virus envelope pro-
ein (HBsAg) (Folgoriet et al., 1994), an epitope from the
epeated region of Plasmodium falciparum circumsporo-
zoite surface protein (CSP) (Stoute et al., 1995), an
epitope from the F protein of respiratory syncytial virus
(Chargelegue et al., 1998), and an epitope from the MVF
protein (Steward et al., 1995). The latter (mimotope M2)
as selected from a solid-phase 8-mer random combi-
atorial peptide library by screening with a monoclonal
ntibody to the F protein of MV. Immunization with M2
99SYNTHETIC PEPTIDE VACCINE AGAINST MEASLES VIRUSinduced antibodies that cross-reacted with MV as well
as conferring protection against fatal encephalitis in-
duced by challenge with neuroadapted MV. Immuniza-
tion with mimotopes synthesized as multiple antigenic
peptides (MAP) (Tam and Lu, 1989; Dedoort et al., 1992;
Chai et al., 1992) has been shown to induce neutralizing
anti-RSV antibodies able to reduce virus load and mono-
nuclear cell infiltration in the lungs of RSV-challenged
mice (Chargelegue et al., 1998).
It is generally accepted that the level of antibodies,
their subclasses, and avidity to infectious agents are
important factors in preventing disease (Steward et al.,
1991; Chargelegue et al., 1995); however, the precise
immunochemical characteristics of biologically effective
antibodies are not known. High-affinity antibodies are
biologically more effective than low-affinity antibodies
but conversely, their production may be associated with
progressive tissue damage in the course of autoimmune
disease (Steward and Chargelegue, 1997). The inability
to produce a high-affinity antibody response may also be
associated with an excessive production of low-affinity
antibodies and this would represent a form of immuno-
defficiency leading to susceptibility to chronic immune
complex disease (Steward, 1979). High-affinity binding of
membrane-bound immunoglobulin to antigen can gener-
ate or inhibit the expression of certain epitopes during
antigen processing (Watts and Lanzavecchia, 1993)
since the processing would affect the complex rather
than the antigen itself. In this manner the affinity of
antibodies may influence which T-cell epitope will dom-
inate and may change the focus of the response, possi-
bly by revealing cryptic epitopes (Watts et al., 1989).
In the work described in this paper, the immunogenic-
ity of different synthetic peptide constructs containing
the sequence of mimotope M2 was compared and it was
FIG. 1. Anti-peptide ELISA antibody titers in BALB/c mice immunized
with different peptides containing mimotope M2. Results are expressed
as the reciprocal of the log10 dilution of serum giving an absorbance of
0.2 at 492 nm. Values represent means and standard deviations for
groups of four mice bled 2 weeks after booster immunization.shown that the affinity of the antibodies induced plays an
important role in protection against MV-induced enceph-
alitis.
RESULTS
Comparison of immunogenicity of synthetic peptides
containing mimotope M2
Serum samples were obtained weekly and were ana-
lyzed to assess the comparative immunogenicity of the
peptides. Data presented in Fig. 1 were obtained from
enzyme-linked immunosorbent assay (ELISA) analysis of
serum samples taken 2 weeks after the booster immu-
nization from mice immunized ip with TM2, TTM2, or
MAP-M2 or coimmunized with M2 plus TT. The results
show the presence of antibodies to M2 in all groups of
mice. However, higher titers were obtained in sera from
animals immunized with the chimeric peptide consisting
of two copies of the T-helper epitope (TTM2) or with
MAP-M2, when compared with groups immunized with
peptide TM2 or coimmunized with M2 plus TT. Similarly,
peptides TTM2 and MAP-M2 generated higher levels of
antibodies reactive with MV than peptides M2 1 TT or
TM2 (P , 0.01) (Fig. 2).
The affinity of the anti-peptide antibodies in these sera
for M2 was determined and the highest affinity values
were detected in sera from mice injected with MAP-M2
(P , 0.001) (Fig. 3). An ELISA-based dissociation assay
was performed with MV on the solid phase to estimate
avidity indices of the antibodies for MV. Avidity indices of
the antibodies for MV following immunization with the
chimera TTM2 and with MAP-M2 (Fig. 4) were signifi-
cantly higher than those of antibodies induced following
immunization with M2 plus TT or with TM2 (P , 0.001).
In vitro proliferative responses of splenocytes primed
with MAP-M2
FIG. 2. Anti-MV ELISA antibody titers in BALB/c mice immunized with
different peptides containing mimotope M2. Results are expressed as
the reciprocal of the serum dilution giving an absorbance of 0.2 at 492
nm. Values represent means and standard deviations for groups of four
mice bled 2 weeks after booster immunization.Lymphocyte proliferation assays were performed with
splenocytes obtained from mice immunized intranasally
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in saline. The results obtained show that upon in vitro
restimulation with MAP-M2, splenocytes from mice im-
munized with MAP-M2 with adjuvants proliferated in a
dose-dependent fashion (Fig. 5a). Proliferative re-
sponses of the T-cell-enriched population of cells to
MAP-M2 were similar to those of unfractionated spleno-
cytes. However, no responses were observed when cells
were restimulated with free M2 peptide or with the un-
related control peptide MAP-B. No responses were de-
tected in the group of mice immunized intranasally with
MAP-M2 in saline (Fig. 5b).
The effect of passive transfer of high-affinity and low-
affinity antibodies on encephalitis induced by
intracranial challenge with neuroadapted MV
For these experiments, the affinity for the mimotope
M2 was assessed for every serum sample obtained at
different time points postimmunization with the different
immunogens containing M2. Sera containing either high-
FIG. 3. The affinity of antibodies for the mimotope M2 induced by
mmunization with the indicated peptide. Results are expressed as
eans and standard deviations (log10 M
21) for groups of four mice bled
weeks after booster immunization.
FIG. 4. Avidity for MV measured by the DEA dissociation method. To
assess the correlation of the results obtained using this method with
results from another technique, 13 samples of serum were tested by
both inhibition ELISA and DEA dissociation. Statistical analysis re-
vealed that both methods rank sera similarly with a correlation coeffi-
cient of 0.71. Results are presented as avidity indices.or low-affinity anti-M2 antibodies were pooled to give
two serum pools. The affinities of antibodies in these
pools for M2 were determined as 3.36 3 107 M21 (high-
affinity pool) and 1.2 3 103 M21 (low-affinity pool). Since
the anti-M2 antibody titers differed in these pools, they
were appropriately diluted to give the same OD values in
ELISA prior to passive transfer to mice (Table 1). Neither
pool had demonstrable in vitro measles neutralizing ac-
tivity nor were there significant differences in immuno-
globulin classes and subclasses between the pools
(data not shown). Following intracranial challenge with
neuroadapted MV, animals were monitored daily for
signs of encephalitis. At the end of the experiment (day
31 postchallenge), all mice in the group that had been
passively immunized with the high-affinity antibody were
still alive (100% survival, P 5 0.0001, compared to mice
eceiving normal serum). Four of eight animals receiving
he low-affinity antibody survived (50% survival, P 5
FIG. 5. Lymphoproliferative responses of splenocytes from mice
immunized intranasally with MAP-M2 1 adjuvant (a) or MAP-M2 1
aline (b). Splenocytes were restimulated in vitro with MAP-M2 (r), M2
), or MAP-B (3) or T-cell-enriched splenocytes were restimulated
ith MAP-M2 (n ). Data are presented as means of three Sls. Maximal
l with Con A was 5.96 for the population of splenocytes and 5.05 for
-cell-enriched splenocytes.0.08, compared to animals receiving normal mouse se-
rum) (Fig. 6). The difference in survival between mice
L101SYNTHETIC PEPTIDE VACCINE AGAINST MEASLES VIRUSreceiving high-affinity and low-affinity antibodies was
significant (P 5 0.02).
DISCUSSION
The work described in this paper is part of a program
of research to investigate the potential of synthetic pep-
tides as vaccines. In this context, the appropriate pre-
sentation of synthetic B- and T-cell epitopes to immune
cells is critical for the induction of antibodies of high
affinity, titer, and immunological memory. Earlier studies
have shown that effective anti-peptide and anti-virus
antibodies could be induced in mice following immuni-
zation with chimeric peptides consisting of either one or
two copies of a promiscuous T-helper epitope (T) from
the F protein of MV covalently coupled to a single copy of
a linear B-cell epitope representing residues 404–414 (B)
from the F protein (TB or TTB, respectively). The TTB
chimera was more immunogenic and induced antibodies
of higher affinity than did the TB peptide. However, the
TTB peptide did not induce antibodies with demonstra-
ble MV-neutralizing activity. It is important to note that
immunization with peptides corresponding to T or TT
alone did not induce antibodies that reacted with the
T
Characterization of High- (H-A) and Low- (L-A) Affini
Serum
Anti-M2 antibody
titer (log10)
Anti-MV antibod
titer (log10)
H-A diluted 2.3 1.04
-A 2.3 1.1
FIG. 6. Effect of passive immunization of BALB/c mice with high-
affinity and low-affinity antibodies on the response to challenge with
the neuroadapted strain of MV. Groups of eight 12-day-old mice re-
ceived 200 ml of high-affinity (r) (log10 antibody titer, 2.3), low-affinity
(n ) (log10 antibody titer, 2.3) or normal mouse serum (*) intraperitoneally
and were challenged 24 h later with MV. Values represent the percent-
age survival in the three groups of mice over 31 days after challenge.virus and had no influence on the response to virus
challenge (Obeid et al., 1995).
In the present studies, we have used peptides con-
taining a mimotope (M2) of a conformational B-cell
epitope, which does not induce antibodies in the ab-
sence of T-cell help (Steward et al., 1995). A peptide
containing two copies of the T epitope coupled to the
mimotope M2 (TTM2) was more effective than a peptide
consisting of only one copy of the T epitope plus M2
(TM2) in terms of immunogenicity and the affinity of the
anti-M2 antibodies induced. It therefore appears that the
mimotope is best presented in the form of TTM2 and it is
possible that the number of copies of a helper T-cell
epitope in a peptide construct influences B-cell activa-
tion, perhaps by increasing the production of cytokines.
This increased “help” may result in increased levels and
affinity of antibody. It is also possible that the length of
the construct containing two T-helper epitopes creates a
conformation that is more efficiently processed and pre-
sented than that formed by the shorter peptide (M2
coimmunized with TT or TM2). However, MAP-M2 does
not include a T-helper epitope in its structure and despite
this, T-help appears to have been generated. The con-
struct is shown here to be immunogenic and able to
induce both anti-peptide and anti-MV reactivity. When the
affinities of the anti-peptide antibodies for M2 generated
by the different constructs were compared, MAP-M2 was
shown to induce significantly higher affinity antibodies
than did the chimeric peptides (TM2 and TTM2) (Fig. 3,
P , 0.001). Thus, it is possible that the addition of lysine
residues from the backbone to the sequence of M2 could
create a conformation that may stimulate helper T-cells
or that more than one M2 sequence is involved in form-
ing a T-helper epitopic structure. In experiments to in-
vestigate this phenomenon, we have shown that the
MAP-M2 peptide induced in vitro proliferation of spleno-
cytes from mice primed with MAP-M2 and adjuvant
whereas M2 and the unrelated peptide MAP-B did not
induce proliferation (Fig. 5a) and proliferative responses
were not observed with splenocytes from mice immu-
nized with MAP-M2 in saline (Fig. 5b). These results
suggest that it is the combination of the M2 amino acid
sequence with the MAP backbone that creates the
epitopic structure capable of providing T-cell help. This
m Pools Used for the Passive Transfer Experiment
Affinity for
M2 (M21) Avidity for MV
In vitro
neutralization
3.36 3 107 47.93 2ve
1.2 3 103 31.77 2veABLE 1
ty Seru
yphenomenon seems to be unique to the present system,
since in related work, we have demonstrated that mimo-
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102 OLSZEWSKA, OBEID, AND STEWARDtopes derived from the F protein of respiratory syncytial
virus presented as MAP constructs in fact required T-
helper coimmunization to induce anti-mimotope antibod-
ies with anti-virus reactivity (Chargelegue et al., 1998).
While we have not formally compared the antibody re-
sponses to the linear 404–414 epitope and the mimotope
in this study, antisera to the two epitopes have similar
anti-MV antibody titers and avidity and are predominantly
of the IgG2a subclass, and some anti-M2 antisera have
MV neutralizing activity (data not shown). Anti-404–414
sera are not MV neutralizing (Steward et al., 1995).
There is a considerable body of literature concerning
the significance of antibody affinity and avidity in deter-
mining the efficacy of antibodies in in vitro reactions and
in disease associations in vivo. However, there is little
information on the importance of these parameters of
antibodies specific for infectious agents in protection in
vivo (Steward and Chargelegue, 1997). In the experi-
ments described here, the role of antibody affinity and
avidity in the protective efficiency of antibodies specific
for MV was formally tested. BALB/c mice were passively
immunized with similar amounts of either high- or low-
affinity MV-specific anti-mimotope antibody prior to intra-
cranial challenge with neuroadapted MV. The anti-mimo-
tope antibodies specifically reacted with, but did not
neutralize, MV in vitro. All mice receiving the high-affinity
antibodies were protected against MV challenge,
whereas 50% of mice receiving the low-affinity antibod-
ies were protected. None of the control mice that re-
ceived normal serum survived the challenge. Although
the difference between groups receiving high- and low-
affinity anti-M2 antisera was statistically significant (P 5
0.02, Fisher’s exact), half of the animals survived, even
though they received low-affinity serum. However, since
differences in avidity indices of the anti-peptide antibod-
ies for MV were not as marked as the differences in
affinity for M2 (Table 1), it is possible that the avidity for
MV in the lower affinity serum pool was close to, or just
above, the protection threshold (Bachmann et al., 1997),
lthough the affinity values for the mimotope were very
ignificantly different. These results clearly indicate the
mportance of affinity and avidity in antibody-mediated
rotection against MV encephalitis.
It is interesting to note that neither of the serum pools
sed neutralized MV in vitro although they both reacted
ell with the virus in an ELISA-type assay.
Even though virus neutralization is clearly an important
roperty of anti-virus antibodies, it is apparent from a
umber of studies that in vitro virus neutralization does
ot always correlate with protective efficacy in vivo (Le-
rancois, 1984; Schmalijohn et al., 1982). The present
esults are consistent with the observation that antibody-
ediated protection against vesicular stomatitis virus
as independent of neutralization, immunoglobulin sub-
lass, and antibody avidity and, above a minimum avidityhreshold, was dependent upon a minimum antibody
oncentration (Bachman et al., 1997).
In conclusion, the data presented here suggest that
imotopes may have potential as components of syn-
hetic peptide vaccines. They are not naturally occurring
equences and, providing their sequences are checked
gainst the known sequences of human proteins, the
isk of inducing autoimmunity would be minimal. The
ata presented here highlight the importance of antibody
oncentration and avidity in antibody-mediated protec-
ion and indicate the necessity for new vaccines to in-
uce antibodies of appropriate avidity. In the case of
ynthetic peptide vaccines, indications are emerging as
o how to design the vaccine to induce a high-affinity and
avidity antibody response. It is likely, however, that vac-
ines for individual infectious agents will require their
wn particular synthetic approach.
MATERIALS AND METHODS
election and synthesis of peptides
Conventional solid-phase peptide synthesis using
moc chemistry was used to synthesize the mimotope
2 and the chimeric peptides TT, TM2, and TTM2 where
represents residues 288–302 of the fusion protein (F) of
V (Partidos and Steward, 1990), a promiscuous
-helper epitope able to provide help for B-cells. Chi-
eric peptides with one or two copies of the T-cell
pitope were colinearly synthesized at the amino-termi-
us of one copy of the M2 epitope with two glycine
esidues as a spacer. MAP-M2 was synthesized using
ommercially available resin with a polylysine backbone
Nova Biochem) to which eight M2 sequences were
dded using Fmoc chemistry. MAP-B, where B repre-
ents a linear B-cell epitope (residues 404–414) of the F
rotein of MV (Partidos et al., 1992a), was synthesized
imilarly. The purity of the peptides was assessed by
igh-pressure liquid chromatography and mass spec-
rometry. The amino acid sequences of the peptides
sed are given in Table 2.
ice
Inbred female BALB/c (H-2d) mice were purchased
from the National Institute of Medical Research (Mill Hill,
UK) and maintained at the London School of Hygiene and
Tropical Medicine (London, UK).
Measles virus
The Edmondston strain of MV was used for the deter-
mination of anti-measles antibody titers and antibody
avidity to the virus in ELISA assays. Rodent-neuroad-
apted MV was originally provided by Dr U. G. Liebert
(Wu¨rzburg, Germany). The virus was injected intracrani-
ally into suckling mice and brain homogenates were
used as the source of virus for challenge studies.
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103SYNTHETIC PEPTIDE VACCINE AGAINST MEASLES VIRUSImmunization of mice
Five- to eight-week-old mice were immunized intra-
peritoneally with 100 mg of peptide TM2, TTM2, or
MAP-M2 or coimmunized with M2 plus TT in Freund’s
complete adjuvant. After 2 weeks the mice were boosted
with the same dose of peptide in Freund’s incomplete
adjuvant. Mice were bled weekly and sera were stored at
220°C.
For intranasal immunization, mice (four per group)
were given 50 mg of MAP-M2 together with 10 mg of each
of the mucosal adjuvants LTR72 (mutant of heat-labile
toxin of Escherichia coli, provided by R. Rappuoli, Siena,
Italy) and CpG repeats with nucleotide sequence TCCAT-
GACGTTCCTGACGTT (synthesized by Pharmacia Bio-
tech). Animals were immunized on days 0, 7, 14, and 28
with a total volume of 30 ml per mouse. A further group of
mice was similarly immunized with 50-mg doses of
MAP-M2 in saline.
Antibody titers: ELISA
Anti-peptide and anti-MV antibody titers were as-
sessed by a solid-phase ELISA on microtiter plates
(Nunc, Roskilde, Denmark). Plates were coated overnight
at 4°C with 50 ml of a 5 mg/ml solution of M2 per well or
with 50 ml of a 5 mg/ml of purified MV in 0.1 M carbonate–
bicarbonate buffer (pH 9.6) per well. The plates were
blocked with 1% BSA in PBS (pH 7.3). Serial twofold
dilutions of sera in phosphate-buffered saline–0.05%
Tween 20–1% BSA (final volume 50 ml) were added to the
plates, which were incubated at 37°C for 1 h and then
washed. Fifty microliters of a 1:2000 dilution of peroxi-
TABLE 2
Notation and Sequences of Peptides Used in the Study
Peptides Sequences
T LSEIKGVIVHRLEGV
M2 NIIRTKKQ
TMS T - Gly - Gly -M2
TTM2 TT - Gly - Gly -M2
MAP-M2
M2
{
M2OLys
{
M2 Lys
{ }
M2OLys {
LysOCysOAlaOOH
M2OLys }
} {
M2 Lys
}
M2OLys
}
M2dase-conjugated rabbit anti-mouse IgG (heavy and light
chains) (Nordic, The Netherlands) was added to eachwell and the plates were incubated for 1 h at 37°C.
Unbound conjugate was removed by washing and 50 ml
f 0.04% o-phenylenediamine–hydrogen peroxidase in
itrate/phosphate buffer was added to detect bound en-
yme. The reaction was stopped after 10 min by the
ddition of 25 ml of 2 M sulfuric acid per well and
absorbance ( A 492) was determined in an automatic plate
reader (Dynex MRX). Titers of anti-peptide and anti-virus
antibodies are expressed as log10 of the reciprocal of the
serum dilution, giving an absorbance of 0.2.
Antibody affinity: Inhibition ELISA
The affinity of anti-peptide antibodies for M2 was as-
sessed by a solid-phase enzyme inhibition assay (Rath
et al., 1988). ELISA plates were coated with M2 at 5
mg/ml and doubling dilutions of sera from mice immu-
nized with chimeric peptides were added. The assay
was continued, as described above, to assess the dilu-
tion of antibody giving an A 492 of 0.6, which was then
sed in the second stage of the assay. Serial dilutions of
3 mM solution of M2 were used to inhibit the binding
f homologous antibody to the solid-phase antigen. The
elative affinity of antibody was calculated as the recip-
ocal of the concentration of peptide giving 50% inhibition
I 0.5) of the binding in the absence of the peptide. These
values represent an estimation of “average” antibody
affinity.
Antibody avidity: ELISA-based dissociation assay
The method is based on the fact that chaotropes, such
as diethylamine (DEA), break noncovalent bonds be-
tween antigen and antibody (Steward and Chargelegue,
1997). Low-avidity antibodies can be easily dissociated
from the antigen in the presence of DEA, while higher
avidity antibodies are more difficult to dissociate. Several
dilutions of DEA were tested to determine the optimal
concentration giving significant antibody dissociation but
not affecting the virus on a plate and 20 mM was chosen.
Four replicates of each working dilution of the sera were
incubated on microtiter plates coated with 5 mg/ml of MV
as described above. After six washes, each duplicate
received either 100 ml of PBS or 100 ml of 20 mM DEA in
PBS, respectively. The samples were incubated for 15
min at room temperature and washed and the assay was
performed as described above. The avidity index (AI)
was calculated as follows:
AI 5
mean of A492 treated with DEA
mean of A492 treated with PBS
3 100.
To maximize the sensitivity of the assay, sera working
dilutions were chosen to give 50% of the maximum OD of
the sample treated with PBS.
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104 OLSZEWSKA, OBEID, AND STEWARDProtection study
The affinity, avidity, and titers of antibodies for M2 from
different bleeds from mice immunized with the different
immunogens were assessed and samples of low affinity
(L-A; affinity values less than 104 M21) and high affinity
H-A; affinity values over 106 M21) were pooled sepa-
ately. The titer and affinity of anti-M2 antibodies in the
wo pools were determined and, because the titers in the
wo pools differed, the H-A serum pool was diluted to
ive the same OD values as the L-A serum pool in ELISA.
wo hundred microliters of either the L-A or the H-A
erum was injected ip into 12-day-old suckling mice.
ormal mouse serum was used in a control group.
wenty-four hours later, mice were intracranially chal-
enged with 104 PFU of neuroadapted MV and animals
were monitored daily for 31 days for the development of
clinical signs.
Neutralization assay
The assay was performed as described (Giraudon and
Wild, 1985). Briefly, serial serum dilutions were incubated
at 37°C in a CO2 incubator with 50 PFU of MV per well in
199 Earl’s medium supplemented with 5% FCS, 0.2%
penicillin/streptomycin, and 5% HEPES. A total of 5 3 104
Vero cells per well were added after 90 min and further
incubated for 3 h at 37°C in 5% CO2. Appropriate cell and
irus controls were included. The medium was dis-
arded and cells were overlaid with 199 Earl’s medium
econstituted in carboxymethyl-cellulose solution sup-
lemented with FCS and penicillin/streptomycin. Incuba-
ion was carried for 4–6 days for the development of
ytopathic effect. After the cells were fixed with methanol
nd stained with crystal violet, the dilution of serum
iving a 50% reduction in plaques was determined. Sera
ailing to reduce plaque numbers by 50% were classified
s nonneutralizing.
ymphocyte proliferation assay
Spleens from MAP-2 immunized mice were removed
septically 2 weeks after the last immunization, trans-
erred to transport medium, teased, and passed through
sieve. Cells were spun at 1200 rpm for 5 min, the
upernatant was discarded, and red blood cells were
ysed using lysing buffer (0.14 M ammonium chloride, 20
M Tris, pH 7.5). B lymphocytes were removed by nylon-
ool chromatography (Julius et al., 1973; Croll et al.,
986). Eluted cells are referred to as the T-cell-enriched
opulation. After three washes in RPMI 1640, cells were
esuspended in complete medium (2% FCS, 0.2% peni-
illin/streptomycin, 1% glutamine, 1% HEPES buffer in
PMI 1640). Three 10-fold dilutions of peptides MAP-M2,
2, and MAP-B and concanavalin A were dispensed into
ells of 96 round-bottomed tissue culture plates. Nega-
ive controls were included. All tests were performed inriplicate. A total of 2 3 105 cells were added to each well
and plates were incubated for 3 days at 37°C in 5% CO2.
Cells were pulsed on the fourth day with tritiated thymi-
dine (1 mCi/well) and harvested 18 h later on glass
microfiber papers. Thymidine incorporation was as-
sessed by liquid scintillation spectrometry. Results are
expressed as stimulation indices of the mean counts per
minute (cpm) from triplicate cultures in the presence of
antigen divided by mean cpm of triplicate cultures with
medium only. Values equal to or higher than 2 were
considered positive.
Statistical analysis
Antibody titers and values of affinity and avidity were
analyzed by a Tukey–Kramer Multiple Comparisons Test.
Fisher’s exact two-tailed test was used for the compari-
son of survival curves in the protection study.
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